在瘤微环境中的非瘤细胞上PD-L1的表达,调节和功能
Lingrong Hu1, Chengliang Sun1, Kai Yuan1
1State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China; Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 211198, China; Institute of Innovative Drug Discovery and Development, China Pharmaceutical University, Nanjing 211198, China.
编程死亡干1 (PD-L1) 免疫疗法在固体癌症中表现出有限的成功. 这项研究总结了PD-L1对免疫细胞的表达及其调节作用,探索治疗耐药性的原因.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 癌症免疫疗法癌症免疫疗法
背景情况:
- 反编程死亡带1 (PD-L1) 疗法是固体癌症的关键免疫疗法.
- 患者受益有限表明潜在的抵抗机制.
- PD-L1在瘤细胞和瘤微环境 (TME) 中的各种免疫细胞上表达.
研究的目的:
- 系统地总结PD-L1在不同免疫细胞上的表达.
- 阐明TME中PD-L1的调节机制.
- 为了解和克服免疫疗法耐药性的基础提供基础.
主要方法:
- 文献综述和现有PD-L1表达研究的系统摘要.
- 分析PD-L1局部化 (免疫细胞,瘤细胞,外体,细胞质).
- 检查PD-L1在调节瘤免疫力和进展中的作用.
主要成果:
- PD-L1表达是动态的,发生在多个位置,包括免疫细胞 (巨细胞,树突细胞,调节性T细胞),瘤细胞,外体和细胞质.
- 这些细胞上的PD-L1影响瘤免疫力和进展.
- 多样化的表达模式可能导致有限的治疗疗效和耐药性.
结论:
- PD-L1的多方面的表达和局部化有助于在抗编程死亡带1疗法中的挑战.
- 了解这些复杂的PD-L1动态对于改善癌症免疫治疗结果至关重要.
- 对PD-L1调节机制的进一步研究可以指导开发更有效的治疗方法.
更多相关视频
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
09:32Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Published on: February 8, 2018
相关概念视频
The Tumor Microenvironment
Abnormal Proliferation
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Regulation of Angiogenesis and Blood Supply
Tumor Immunotherapy
